RT Book, Section
A1 Hemstreet, Brian A.
A2 DiPiro, Joseph T.
A2 Yee, Gary C.
A2 Haines, Stuart T.
A2 Nolin, Thomas D.
A2 Ellingrod, Vicki L.
A2 Posey, L. Michael
SR Print(0)
ID 1205566115
T1 Inflammatory Bowel Disease
T2 DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition
YR 2023
FD 2023
PB McGraw Hill
PP New York, NY
SN 9781264264544
LK accesspharmacy.mhmedical.com/content.aspx?aid=1205566115
RD 2024/04/20
AB Update  SummaryFebruary  1,  2023The  following  sections,  tables,  and  figures  were  updated:Key  Concepts:  upadacitinib  added  to  key  concept  8,  and  rizankizuman-rzaa  added  to  key  concept  11Beyond  The  Book:  part  d  revisedFigure  52-2:  risankizumab-rzaa  addedTable  52-4:  rizankizumab-rzaa  and  upadacitinib  addedFigure  52-3:  updated  based  on  new  guidelines  to  include  new  therapiesTable  52-5:  upadacitinib  and  rizankizumab-rzaa  addedAdverse  Drug  Effects:  edits  made  to  include  upadacitinib  and  risankizumab-rzaaSpecial  Populations,  Pregnancy,  and  Breastfeeding:  information  added  for  upadacitinib  and  risankizumab-rzaa